Tags

Type your tag names separated by a space and hit enter

Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus.
Diabetologia. 2002 Mar; 45(3):420-6.D

Abstract

AIM/HYPOTHESIS

We assessed whether dietary supplementation with coenzyme Q(10) improves endothelial function of the brachial artery in patients with Type II (non-insulin-dependent) diabetes mellitus and dyslipidaemia.

METHODS

A total of 40 patients with Type II diabetes and dyslipidaemia were randomized to receive 200 mg of coenzyme Q(10) or placebo orally for 12 weeks. Endothelium-dependent and independent function of the brachial artery was measured as flow-mediated dilatation and glyceryl-trinitrate-mediated dilatation, respectively. A computerized system was used to quantitate vessel diameter changes before and after intervention. Arterial function was compared with 18 non-diabetic subjects. Oxidative stress was assessed by measuring plasma F(2)-isoprostane concentrations, and plasma antioxidant status by oxygen radical absorbance capacity.

RESULTS

The diabetic patients had impaired flow-mediated dilation [3.8 % (SEM 0.5) vs 6.4 % (SEM 1.0), p = 0.016], but preserved glyceryl-trinitrate-mediated dilation, of the brachial artery compared with non-diabetic subjects. Flow-mediated dilation of the brachial artery increased by 1.6 % (SEM 0.3) with coenzyme Q(10) and decreased by -0.4 % (SEM 0.5) with placebo (p = 0.005); there were no group differences in the changes in pre-stimulatory arterial diameter, post-ischaemic hyperaemia or glyceryl-trinitrate-mediated dilation response. Coenzyme Q(10) treatment resulted in a threefold increase in plasma coenzyme Q(10) (p < 0.001) but did not alter plasma F(2)-isoprostanes, oxygen radical absorbance capacity, lipid concentrations, glycaemic control or blood pressure.

CONCLUSION/INTERPRETATION

Coenzyme Q(10) supplementation improves endothelial function of conduit arteries of the peripheral circulation in dyslipidaemic patients with Type II diabetes. The mechanism could involve increased endothelial release and/or activity of nitric oxide due to improvement in vascular oxidative stress, an effect that might not be reflected by changes in plasma F(2)-isoprostane concentrations.

Authors+Show Affiliations

Department of Medicine, University of Western Australia, Royal Perth Hospital, Perth, Australia. gfwatts@cyllene.uwa.edu.auNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11914748

Citation

Watts, G F., et al. "Coenzyme Q(10) Improves Endothelial Dysfunction of the Brachial Artery in Type II Diabetes Mellitus." Diabetologia, vol. 45, no. 3, 2002, pp. 420-6.
Watts GF, Playford DA, Croft KD, et al. Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia. 2002;45(3):420-6.
Watts, G. F., Playford, D. A., Croft, K. D., Ward, N. C., Mori, T. A., & Burke, V. (2002). Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. Diabetologia, 45(3), 420-6.
Watts GF, et al. Coenzyme Q(10) Improves Endothelial Dysfunction of the Brachial Artery in Type II Diabetes Mellitus. Diabetologia. 2002;45(3):420-6. PubMed PMID: 11914748.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q(10) improves endothelial dysfunction of the brachial artery in Type II diabetes mellitus. AU - Watts,G F, AU - Playford,D A, AU - Croft,K D, AU - Ward,N C, AU - Mori,T A, AU - Burke,V, PY - 2002/3/27/pubmed PY - 2002/8/22/medline PY - 2002/3/27/entrez SP - 420 EP - 6 JF - Diabetologia JO - Diabetologia VL - 45 IS - 3 N2 - AIM/HYPOTHESIS: We assessed whether dietary supplementation with coenzyme Q(10) improves endothelial function of the brachial artery in patients with Type II (non-insulin-dependent) diabetes mellitus and dyslipidaemia. METHODS: A total of 40 patients with Type II diabetes and dyslipidaemia were randomized to receive 200 mg of coenzyme Q(10) or placebo orally for 12 weeks. Endothelium-dependent and independent function of the brachial artery was measured as flow-mediated dilatation and glyceryl-trinitrate-mediated dilatation, respectively. A computerized system was used to quantitate vessel diameter changes before and after intervention. Arterial function was compared with 18 non-diabetic subjects. Oxidative stress was assessed by measuring plasma F(2)-isoprostane concentrations, and plasma antioxidant status by oxygen radical absorbance capacity. RESULTS: The diabetic patients had impaired flow-mediated dilation [3.8 % (SEM 0.5) vs 6.4 % (SEM 1.0), p = 0.016], but preserved glyceryl-trinitrate-mediated dilation, of the brachial artery compared with non-diabetic subjects. Flow-mediated dilation of the brachial artery increased by 1.6 % (SEM 0.3) with coenzyme Q(10) and decreased by -0.4 % (SEM 0.5) with placebo (p = 0.005); there were no group differences in the changes in pre-stimulatory arterial diameter, post-ischaemic hyperaemia or glyceryl-trinitrate-mediated dilation response. Coenzyme Q(10) treatment resulted in a threefold increase in plasma coenzyme Q(10) (p < 0.001) but did not alter plasma F(2)-isoprostanes, oxygen radical absorbance capacity, lipid concentrations, glycaemic control or blood pressure. CONCLUSION/INTERPRETATION: Coenzyme Q(10) supplementation improves endothelial function of conduit arteries of the peripheral circulation in dyslipidaemic patients with Type II diabetes. The mechanism could involve increased endothelial release and/or activity of nitric oxide due to improvement in vascular oxidative stress, an effect that might not be reflected by changes in plasma F(2)-isoprostane concentrations. SN - 0012-186X UR - https://www.unboundmedicine.com/medline/citation/11914748/Coenzyme_Q_10__improves_endothelial_dysfunction_of_the_brachial_artery_in_Type_II_diabetes_mellitus_ L2 - https://doi.org/10.1007/s00125-001-0760-y DB - PRIME DP - Unbound Medicine ER -